We are live on ! Find out more
SPA

Sherbrooke Park Advisers Portfolio holdings

AUM $38.7M
1-Year Est. Return 5.29%
This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
-5.29%
3 Year Est. Return
-9.59%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$15.6M
Cap. Flow
+$5.46M
Cap. Flow %
2.37%
Top 10 Hldgs %
6.97%
Holding
827
New
263
Increased
114
Reduced
126
Closed
324

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.45M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.42M
3
G icon
Genpact
G
+$1.42M
4
CHRW icon
C.H. Robinson
CHRW
+$1.34M
5
OGE icon
OGE Energy
OGE
+$1.31M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$1.44M
2
MDLZ icon
Mondelez International
MDLZ
+$1.42M
3
AVT icon
Avnet
AVT
+$1.21M
4
MRVL icon
Marvell Technology
MRVL
+$1.04M
5
XYZ
Block Inc
XYZ
+$987K

Sector Composition

Rank Sector Weight
1 Technology 21.25%
2 Consumer Discretionary 15.35%
3 Healthcare 13.63%
4 Industrials 12.99%
5 Financials 10.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACCD
826
DELISTED
Accolade Inc
ACCD
– –
-61,696
Closed -$431K
NVRO
827
DELISTED
NEVRO CORP.
NVRO
– –
-17,386
Closed -$102K
30 31 32 33
34

Similar funds

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 13.88% 1-Year Est. Return
ISSM
Invesco Senior Secured Management New York $40.9M AUM 3.88% 1-Year Est. Return
KCM
Kawa Capital Management Hallandale Beach, Florida $43.2M AUM 13.52% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
APM
Advanced Portfolio Management New York $32.8M AUM 6.64% 1-Year Est. Return
CI
Centerstone Investors New York $31.8M AUM 32.46% 1-Year Est. Return

Sherbrooke Park Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, Sherbrooke Park Advisers held 827 positions worth $230M, up 7.3% from $215M the previous quarter. Its ten largest holdings account for 7% of the portfolio.

Sherbrooke Park Advisers's Q2 2025 filing shows 263 new, 114 increased, 126 reduced and 324 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 24,678 shares worth $1.36M. The largest sale was Merck, an estimated $1.44M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Sherbrooke Park Advisers's largest Q2 2025 buy was BioMarin Pharmaceuticals: 24,678 shares worth $1.36M.
  • Sherbrooke Park Advisers added most to CMS Energy in Q2 2025, an estimated $1.14M increase.
  • Sherbrooke Park Advisers's biggest Q2 2025 reduction was MasTec, cutting an estimated $947K.
  • Sherbrooke Park Advisers fully exited Merck in Q2 2025, selling an estimated $1.44M.
  • Sherbrooke Park Advisers's ten largest holdings make up 7% of its $230M portfolio in Q2 2025.
  • Sherbrooke Park Advisers opened 263 new positions and closed 324 in Q2 2025.
  • Sherbrooke Park Advisers's portfolio value rose 7.3% quarter-over-quarter to $230M.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.